XML 27 R16.htm IDEA: XBRL DOCUMENT
v3.25.1

SEGMENTS | 3 Months Ended
--- | ---
Mar. 31, 2025
SEGMENTS [Abstract] |
SEGMENTS | 10. SEGMENTS The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The Company’s ADMA BioManufacturing operating segment reflects the Company’s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL. The Plasma Collection Centers operating segment consists of ten plasma collection facilities located throughout the United States, all of which are operational, collecting plasma and currently hold FDA licenses. The Company defines its operating segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources. While not considered an operating segment, the Corporate information included in the tables below consists of certain unallocated general and administrative overhead expenses and interest expense on the Company’s senior debt (see Note 7). The Company’s CODM is its President and Chief Executive Officer. For the Company’s two operating segments, the CODM uses income/loss before taxes as the measure of segment profit to determine the allocation of resources for each segment. Summarized financial information concerning reportable segments is shown in the following tables:
Three Months Ended March 31, 2025
(in thousands) |  | ADMA BioManufacturing |  |  |  | Plasma Collection Centers |  |  |  | Total |
Revenues | $ | 113,716 |  |  | $ | 1,050 |  |  | $ | 114,766 |
Cost of product revenue |  | 53,057 |  |  |  | 648 |  |  |  | 53,705 |
Research and development |  | 826 |  |  |  | - |  |  |  | 826 |
Plasma center operating expenses |  | - |  |  |  | 1,286 |  |  |  | 1,286 |
Selling, marketing and distribution |  | 6,044 |  |  |  | - |  |  |  | 6,044 |
Depreciation and amortization expense |  | 25 |  |  |  | - |  |  |  | 25 |
General and administrative expense |  | 8,495 |  |  |  | - |  |  |  | 8,495 |
Other expense, net |  | (64 | ) |  |  | - |  |  |  | (64 | )
Income (loss) before taxes |  | 45,205 |  |  |  | (884 | ) |  |  | 44,321 |
Expenditures for additions to long-lived assets |  | 4,699 |  |  |  | 21 |  |  |  | 4,720 |
Total assets |  | 330,091 |  |  |  | 27,644 |  |  |  | 357,735 |
Reconciliation of revenues: |  |  |  |  |  |  |  |  |  |  |
Segment revenue |  |  |  |  |  |  |  |  | $ | 114,766 |
License revenue |  |  |  |  |  |  |  |  |  | 36 |
Consolidated revenues |  |  |  |  |  |  |  |  | $ | 114,802 |
Reconciliation of selling, general and administrative expense: |  |  |  |  |  |  |  |  |  |  |
Segment selling, marketing and distribution expense |  |  |  |  |  |  |  |  | $ | 6,044 |
Segment general and administrative expense |  |  |  |  |  |  |  |  |  | 8,495 |
Corporate general and administrative expense (a) |  |  |  |  |  |  |  |  |  | 9,540 |
Consolidated selling, general and administrative expense |  |  |  |  |  |  |  |  | $ | 24,079 |
Reconciliation of income (loss) before taxes: |  |  |  |  |  |  |  |  |  |  |
Segment income before taxes |  |  |  |  |  |  |  |  | $ | 44,321 |
License revenue |  |  |  |  |  |  |  |  |  | 36 |
Unallocated interest expense, primarily related to interest on senior debt (see Note 6) |  |  |  |  |  |  |  |  |  | (1,975 | )
Unallocated interest income |  |  |  |  |  |  |  |  |  | 608 |
Corporate general and administrative expense (a) |  |  |  |  |  |  |  |  |  | (9,540 | )
Consolidated income before taxes |  |  |  |  |  |  |  |  | $ | 33,450 |
Reconciliation of total assets: |  |  |  |  |  |  |  |  |  |  |
Total segment assets |  |  |  |  |  |  |  |  | $ | 357,735 |
Corporate (b) |  |  |  |  |  |  |  |  |  | 152,834 |
Consolidated total assets |  |  |  |  |  |  |  |  | $ | 510,569 |
(a) - Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments. (b) - Primarily consists of cash and deferred tax assets.
Three Months Ended March 31, 2024
(in thousands) |  | ADMA BioManufacturing |  |  |  | Plasma Collection Centers |  |  |  | Total |
Revenues | $ | 80,113 |  |  | $ | 1,726 |  |  | $ | 81,839 |
Cost of product revenue |  | 40,991 |  |  |  | 1,776 |  |  |  | 42,767 |
Research and development |  | 451 |  |  |  | - |  |  |  | 451 |
Plasma center operating expenses |  | - |  |  |  | 1,005 |  |  |  | 1,005 |
Selling, marketing and distribution |  | 4,431 |  |  |  | - |  |  |  | 4,431 |
Depreciation and amortization expense |  | 193 |  |  |  | - |  |  |  | 193 |
General and administrative expense |  | 5,351 |  |  |  | - |  |  |  | 5,351 |
Other expense, net |  | (30 | ) |  |  | (1 | ) |  |  | (31 | )
Income (loss) before taxes |  | 28,666 |  |  |  | (1,056 | ) |  |  | 27,610 |
Expenditures for additions to long-lived assets |  | 2,330 |  |  |  | 17 |  |  |  | 2,347 |
Total assets |  | 278,331 |  |  |  | 33,990 |  |  |  | 312,321 |
Reconciliation of revenues: |  |  |  |  |  |  |  |  |  |  |
Segment revenue |  |  |  |  |  |  |  |  | $ | 81,839 |
License revenue |  |  |  |  |  |  |  |  |  | 36 |
Consolidated revenues |  |  |  |  |  |  |  |  | $ | 81,875 |
Reconciliation of selling, general and administrative expense: |  |  |  |  |  |  |  |  |  |  |
Segment selling, marketing and distribution expense |  |  |  |  |  |  |  |  | $ | 4,431 |
Segment general and administrative expense |  |  |  |  |  |  |  |  |  | 5,351 |
Corporate general and administrative expense (a) |  |  |  |  |  |  |  |  |  | 5,857 |
Consolidated selling, general and administrative expense |  |  |  |  |  |  |  |  | $ | 15,639 |
Reconciliation of income (loss) before taxes: |  |  |  |  |  |  |  |  |  |  |
Segment income before taxes |  |  |  |  |  |  |  |  | $ | 27,610 |
License revenue |  |  |  |  |  |  |  |  |  | 36 |
Unallocated interest expense, primarily related to interest on senior debt (see Note 6) |  |  |  |  |  |  |  |  |  | (3,769 | )
Unallocated interest income |  |  |  |  |  |  |  |  |  | 381 |
Corporate general and administrative expense (a) |  |  |  |  |  |  |  |  |  | (5,857 | )
Consolidated income before taxes |  |  |  |  |  |  |  |  | $ | 18,401 |
Reconciliation of total assets: |  |  |  |  |  |  |  |  |  |  |
Total segment assets |  |  |  |  |  |  |  |  | $ | 312,321 |
Corporate (b) |  |  |  |  |  |  |  |  |  | 38,554 |
Consolidated total assets |  |  |  |  |  |  |  |  | $ | 350,875 |
(a) - Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments. (b) - Primarily consists of cash and deferred tax assets. Net revenues according to geographic area, based on the location of where the product is shipped, were as follows:
| Three Months Ended March 31, 2025
|  | ADMA BioManufacturing |  |  |  | Plasma Centers |  |  |  | Total Segment Revenue |  |  |  | License Revenue |  |  |  | Consolidated Revenue |
United States | $ | 110,609 |  |  | $ | 85 |  |  | $ | 110,694 |  |  | $ | 36 |  |  | $ | 110,730 |
International |  | 3,107 |  |  |  | 965 |  |  |  | 4,072 |  |  |  | - |  |  |  | 4,072 |
Total revenues | $ | 113,716 |  |  | $ | 1,050 |  |  | $ | 114,766 |  |  | $ | 36 |  |  | $ | 114,802 |
| Three Months Ended March 31, 2024
|  | ADMA BioManufacturing |  |  |  | Plasma Centers |  |  |  | Total Segment Revenue |  |  |  | License Revenue |  |  |  | Consolidated Revenue |
United States | $ | 76,460 |  |  | $ | 1,495 |  |  | $ | 77,955 |  |  | $ | 36 |  |  | $ | 77,991 |
International |  | 3,653 |  |  |  | 231 |  |  |  | 3,884 |  |  |  | - |  |  |  | 3,884 |
Total revenues | $ | 80,113 |  |  | $ | 1,726 |  |  | $ | 81,839 |  |  | $ | 36 |  |  | $ | 81,875 |

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54 Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContent Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21 Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration